Physician profile
George Abraham
NPI 1932377884
$3,380.77
in general payments reported to CMS, 2019-2025
13 companies · $674 in 2025
The $674 reported for 2025 was more than what 92% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $961 · 2020: $95.46 · 2021: $469 · 2022: $237 · 2023: $571 · 2024: $374 · 2025: $674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,618.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,618.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $839.29 | 2019-2025 | Breztri, Airsupra, Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $680.74 | 2019-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $442.55 | 2019-2024 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $314.81 | 2019-2025 | Xifaxan |
| Alexion Pharmaceuticals, INC. | $271.20 | 2020-2025 | Ultomiris |
| Abbvie INC. | $213.22 | 2023-2025 | Mavyret |
| E.R. Squibb & Sons, L.L.C. | $160.02 | 2019-2023 | Camzyos |
| Sunovion Pharmaceuticals INC. | $148.18 | 2019 | |
| Lilly USA, LLC | $124.00 | 2025 | Zepbound |
| Allergan, INC. | $118.77 | 2019 | |
| Novartis Pharmaceuticals Corporation | $28.11 | 2019 | |
| Pfizer INC. | $27.98 | 2019 | |
| Merck Sharp & Dohme LLC | $11.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.